Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.74 USD
Change Today -0.01 / -0.21%
Volume 284.0K
ANTH On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

anthera pharmaceuticals inc (ANTH) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - $6.37
52 Week Low
12/23/14 - $1.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

anthera pharmaceuticals inc (ANTH) Related Bloomberg News

View More Bloomberg News

anthera pharmaceuticals inc (ANTH) Related Businessweek News

No Related Businessweek News Found

anthera pharmaceuticals inc (ANTH) Details

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others. The company is also developing a Phase III product candidate Liprotamase, a non-porcine investigational pancreatic enzyme replacement therapy intended for the treatment of patients with exocrine pancreatic insufficiency. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

20 Employees
Last Reported Date: 03/16/15
Founded in 2004

anthera pharmaceuticals inc (ANTH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $515.0K
Principal Accounting Officer, Compliance Offi...
Total Annual Compensation: $261.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $350.0K
Chief Technology Officer and Senior Vice Pres...
Total Annual Compensation: $340.0K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

anthera pharmaceuticals inc (ANTH) Key Developments

Anthera Pharmaceuticals, Inc. Announces Amendments to the Bylaws

On May 21, 2015, the Board of Directors of Anthera Pharmaceuticals, Inc. approved and adopted an amendment to the company's Bylaws which amends and restates Section 11 of the Bylaws to provide that unless the company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on behalf of the company, any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the company to the company or the company's stockholders, any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or the Certificate or Bylaws, or any action asserting a claim against the company governed by the internal affairs doctrine.

Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Anthera Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced loss from operations of $7,657,000 compared to $7,609,000 for the same period a year ago. Net loss was $7,660,000 compared to $7,916,000 for the same period a year ago. Net loss per share, basic and diluted were $0.28 compared to $0.39 for the same period a year ago. Total Revenue was $245,000.

Anthera Pharmaceuticals, Inc., Annual General Meeting, May 21, 2015

Anthera Pharmaceuticals, Inc., Annual General Meeting, May 21, 2015., at 11:00 Pacific Standard Time. Location: Goodwin Procter LLP, Three Embarcadero Center. Agenda: To elect three class III directors, as nominated by the board of directors, to hold office until the 2018 annual meeting of stockholders or until their successors are duly elected and qualified; to ratify the appointment of BDO USA, LLP as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2015; to approve an amendment to the 2013 stock option and incentive plan to increase the aggregate number of shares authorized for issuance under the plan by 1,790,818 shares; and to transact such other business as may properly come before the meeting or any adjournment or postponement thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANTH:US $4.74 USD -0.01

ANTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANTH.
View Industry Companies

Industry Analysis


Industry Average

Valuation ANTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 533.9x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 522.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTHERA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at